SHILPA MEDICARE
|
|
BOM : 530549     NSE : SHILPAMED     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : High [>50%] |
Sep 06,2024 |
Price(EOD): ₹ 808.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 7,908.60 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SHILPA MEDICARE | 6.1% | 14.4% | 123.6% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 5.1% | 64.6% |
CIPLA | -2.1% | 3.7% | 30.8% |
DR REDDYS LABORATORIES | -2.9% | -3.7% | 20.1% |
ZYDUS LIFESCIENCES | -1% | -13.6% | 81.7% |
DIVIS LABORATORIES | 2.1% | 3.9% | 42.8% |
FUNDAMENTAL ANALYSIS OF SHILPA MEDICARE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SHILPA MEDICARE
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
153.63
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 51.47 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 4.37
P/B Calculated based on Book Value of Rs 1,808.69 Cr
[Latest Year - Mar2024 - Consolidated Results ] 6.68
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,183.66 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
578% 99% 107% |
SHARE PRICE MOMENTUM OF SHILPA MEDICARE
SHILPA MEDICARE vs SENSEX
DEBT OF SHILPA MEDICARE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.07 0.14 0.09 0.1 |
0.52 0.45 0.37 0.45 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SHILPA MEDICARE
Pledged Promoter Shares |
90.41 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SHILPA MEDICARE
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.28% 5.05% 15.59% -28.66% |
12.43% 53.59% 550.05% 519.23% |
QtrlyTrend |
6 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
SHILPA MEDICARE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.7% | 8.6% | 55.8% |
S&P BSE SMALL CAP | -0.1% | 7.6% | 50.7% |
S&P BSE MIDSMALLCAP | -0.6% | 7% | 53.1% |
S&P BSE ALLCAP | -1.1% | 4.7% | 39.1% |
You may also like the below Video Courses
FAQ about SHILPA MEDICARE
Is SHILPA MEDICARE good for long term investment?
As on Sep 06,2024, the Fundamentals of SHILPA MEDICARE look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SHILPA MEDICARE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SHILPA MEDICARE UnderValued or OverValued?
As on Sep 06,2024, SHILPA MEDICARE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SHILPA MEDICARE ?
As on Sep 06,2024, the Intrinsic Value of SHILPA MEDICARE is Rs. 391.30 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 119.25
Fair Value [Median EV / Sales Model] : Rs. 405.51
Fair Value [Median Price / Sales Model] : Rs. 391.30
Estimated Median Fair Value of SHILPA MEDICARE : Rs. 391.30
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.